Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne M Fagan

Showing results (151-160 of 279) with videos related to

Pageof 28
Sort By:
Annals of Clinical and Translational Neurology|October 2, 2022
Comparison of plasma and CSF biomarkers in predicting cognitive declineAndrew J Aschenbrenner, Yan Li, Rachel L Henson, et al.
The Journal of Clinical Investigation|October 22, 2005
P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse modelJohn R Cirrito, Rashid Deane, Anne M Fagan, et al.
Plos Genetics|August 31, 2013
The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-ε4 carriersBruno A Benitez, Celeste M Karch, Yefei Cai, et al.
Alzheimer'S Research & Therapy|September 27, 2018
Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's diseaseUmesh Gangishetti, J Christina Howell, Richard J Perrin, et al.
Annals of Neurology|December 24, 2005
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humansAnne M Fagan, Mark A Mintun, Robert H Mach, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 26, 2018
The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A reviewOskar Hansson, Alvydas Mikulskis, Anne M Fagan, et al.
Sleep|March 18, 2022
Adverse driving behaviors are associated with sleep apnea severity and age in cognitively normal older adults at risk for Alzheimer's diseaseJason M Doherty, Catherine M Roe, Samantha A Murphy, et al.
Neuroimage. Clinical|March 23, 2019
Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's diseaseQing Wang, Yong Wang, Jingxia Liu, et al.
Brain and Behavior|February 28, 2018
Neurodegenerative disease biomarkers Aβ<sub>1-40</sub>, Aβ<sub>1-42</sub>, tau, and p-tau<sub>181</sub> in the vervet monkey cerebrospinal fluid: Relation to normal aging, genetic influences, and cerebral amyloid angiopathyJason A Chen, Scott C Fears, Anna J Jasinska, et al.
Clinical Chemistry|March 11, 2018
Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison StudyEline A J Willemse, Ann De Vos, Elizabeth M Herries, et al.
Pageof 28

Showing results (151-160 of 279) with videos related to

Sort By:
Pageof 28
Annals of Clinical and Translational Neurology|October 2, 2022
Comparison of plasma and CSF biomarkers in predicting cognitive declineAndrew J Aschenbrenner, Yan Li, Rachel L Henson, et al.
The Journal of Clinical Investigation|October 22, 2005
P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse modelJohn R Cirrito, Rashid Deane, Anne M Fagan, et al.
Plos Genetics|August 31, 2013
The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-ε4 carriersBruno A Benitez, Celeste M Karch, Yefei Cai, et al.
Alzheimer'S Research & Therapy|September 27, 2018
Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's diseaseUmesh Gangishetti, J Christina Howell, Richard J Perrin, et al.
Annals of Neurology|December 24, 2005
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humansAnne M Fagan, Mark A Mintun, Robert H Mach, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 26, 2018
The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A reviewOskar Hansson, Alvydas Mikulskis, Anne M Fagan, et al.
Sleep|March 18, 2022
Adverse driving behaviors are associated with sleep apnea severity and age in cognitively normal older adults at risk for Alzheimer's diseaseJason M Doherty, Catherine M Roe, Samantha A Murphy, et al.
Neuroimage. Clinical|March 23, 2019
Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's diseaseQing Wang, Yong Wang, Jingxia Liu, et al.
Brain and Behavior|February 28, 2018
Neurodegenerative disease biomarkers Aβ<sub>1-40</sub>, Aβ<sub>1-42</sub>, tau, and p-tau<sub>181</sub> in the vervet monkey cerebrospinal fluid: Relation to normal aging, genetic influences, and cerebral amyloid angiopathyJason A Chen, Scott C Fears, Anna J Jasinska, et al.
Clinical Chemistry|March 11, 2018
Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison StudyEline A J Willemse, Ann De Vos, Elizabeth M Herries, et al.
Pageof 28